SCHEMBL13337173

SCHEMBL13337173

CC(C)C(=O)C(N)CCCCN

nearest known ligand 0.59

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
GSR P00390 1/20 0.59
GNAI3 P08754 1/20 0.46
GNAO1 P09471 1/20 0.46
GNAI1 P63096 1/20 0.46
DPP7 Q9UHL4 8/20 0.42
DPP8 Q6V1X1 4/20 0.42
DPP9 Q86TI2 4/20 0.42
RNPEP Q9H4A4 1/20 0.42
DPP4 P27487 2/20 0.41
CPB2 Q96IY4 4/20 0.38
TRPV1 Q8NER1 1/20 0.38
TRPA1 O75762 1/20 0.38
FAP Q12884 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10046226 1.00 GSR (0.59) GSRGNAI3GNAO1GNAI1DPP7
SCHEMBL10046228 1.00 GSR (0.59) GSRGNAI3GNAO1GNAI1DPP7
SCHEMBL20383848 0.98 GSR (0.57) GSRGNAI3GNAO1GNAI1DPP7
SCHEMBL20388836 0.98 GSR (0.57) GSRGNAI3GNAO1GNAI1DPP7
SCHEMBL13429506 0.98 GSR (0.57) GSRGNAI3GNAO1GNAI1DPP7
SCHEMBL23762407 0.98 GSR (0.57) GSRGNAI3GNAO1GNAI1DPP7
SCHEMBL12280588 0.93 GSR (0.50) GSRGNAI3GNAO1GNAI1DPP7
SCHEMBL12278737 0.93 GSR (0.50) GSRGNAI3GNAO1GNAI1DPP7
SCHEMBL17173859 0.93 GSR (0.50) GSRGNAI3GNAO1GNAI1DPP7
SCHEMBL4761845 0.84 GABRR1 (0.46) GSRDPP7DPP8DPP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11859231-B2 Multilayer electrochemical analyte sensors and methods for making and using them MEDTRONIC MINIMED, INC. (US) 2024-01-02 US disclosed
EP-4276090-A1 CATIONIC LIPID, LIPOSOME CONTAINING CATIONIC LIPID, AND NUCLEIC-ACID PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME AND PREPARATION AND APPLICATION THEREOF Xiamen Sinopeg Biotech Co., Ltd. (CN) 2023-11-15 EP disclosed
US-20230322743-A1 NOVEL SAFRYLAMINE DERIVATIVES HAVING PRODRUG PROPERTIES MIHKAL GMBH (CH) 2023-10-12 US disclosed
US-20230322743-A1 NOVEL SAFRYLAMINE DERIVATIVES HAVING PRODRUG PROPERTIES MIHKAL GMBH (CH) 2023-10-12 US disclosed
US-20230227420-A1 PRODRUGS OF MDMA, MDA, AND DERIVATIVES THEREOF EMPATHBIO, INC. 2023-07-20 US disclosed
US-20230030115-A1 RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF BEIJING TIDE PHARMACEUTICAL CO LTD (CN) 2023-02-02 US disclosed
US-20220119492-A1 IL-2R-BETA-GAMMA BINDING COMPOUNDS AND USES THEREOF JEFFREY W. AND CHRISTINA R. BIRD TRUST U/A/D 2022-04-21 US disclosed
WO-2021221656-A1 COMPOSITIONS AND METHODS OF USE THEREOF SYNEDGEN, INC. (US) 2021-11-04 WO disclosed
US-11078164-B1 PTEN binding compounds, formulations, and uses thereof UNIVERSITY OF SOUTH FLORIDA (US) 2021-08-03 US disclosed
US-20200339581-A1 AMINO INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2020-10-29 US disclosed
EP-3311823-A1 METHODS AND COMPOSITIONS FOR DISRUPTING BIOFILM UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS Synedgen, Inc. (US) 2018-04-25 EP disclosed
US-9745335-B2 N-substituted second generation derivatives of antifungal antibiotic amphotericin B and methods of their preparation and application BLIRT S.A. (PL) 2017-08-29 US disclosed
US-9745335-B2 N-substituted second generation derivatives of antifungal antibiotic amphotericin B and methods of their preparation and application BLIRT S.A. (PL) 2017-08-29 US disclosed
EP-2473042-B1 METHODS AND COMPOSITIONS FOR DISRUPTING BIOFILM UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS SYNEDGEN INC (US) 2017-08-02 EP disclosed
WO-2017019833-A1 COMPOSITIONS CONTAINING REPAIR CELLS AND CATIONIC DYES MEDIVATION TECHNOLOGIES, INC. (US) 2017-02-02 WO disclosed
US-20150291648-A1 N-SUBSTITUTED SECOND GENERATION DERIVATIVES OF ANTIFUNGAL ANTIBIOTIC AMPHOTERICIN B AND METHODS OF THEIR PREPARATION AND APPLICATION BLIRT S.A. (PL) 2015-10-15 US disclosed
US-8709431-B2 Enediyne compounds, conjugates thereof, and uses and methods therefor BRISTOL-MYERS SQUIBB COMPANY (US) 2014-04-29 US disclosed
US-20130209494-A1 ENEDIYNE COMPOUNDS, CONJUGATES THEREOF, AND USES AND METHODS THEREFOR BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-15 US disclosed
WO-2012148550-A1 PRODRUGS OF THERAPEUTIC COMPOUNDS MYREXIS, INC. (US) 2012-11-01 WO disclosed
US-20100130581-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN THE UNIVERSITY OF QUEENSLAND 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227420-A1 PRODRUGS OF MDMA, MDA, AND DERIVATIVES THEREOF COMT, PNMT, ABCB1 GSR 319/4885GNAI3 4214/4885GNAO1 3614/4885
US-20100130581-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN OPRL1, CRH, OPRK1 GSR 2211/4885GNAI3 1991/4885GNAO1 1287/4885
US-11078164-B1 PTEN binding compounds, formulations, and uses thereof PTEN, EYA2, PIK3CA GSR 4681/4885GNAI3 409/4885GNAO1 867/4885
US-20150291648-A1 N-SUBSTITUTED SECOND GENERATION DERIVATIVES OF ANTIFUNGAL ANTIBIOTIC AMPHOTERICIN B AND METHODS OF THEIR PREPARATION AND APPLICATION ERG28, LSS, NPC1 GSR 1576/4885GNAI3 3090/4885GNAO1 3124/4885
US-20230322743-A1 NOVEL SAFRYLAMINE DERIVATIVES HAVING PRODRUG PROPERTIES HTR2A, HTR2C, HTR1D GSR 1842/4885GNAI3 3547/4885GNAO1 3255/4885
US-20130209494-A1 ENEDIYNE COMPOUNDS, CONJUGATES THEREOF, AND USES AND METHODS THEREFOR ECI1, DHFR, NQO1 GSR 142/4885GNAI3 1102/4885GNAO1 1990/4885
US-20220119492-A1 IL-2R-BETA-GAMMA BINDING COMPOUNDS AND USES THEREOF IL2RA, IL2, IL15RA GSR 1423/4885GNAI3 735/4885GNAO1 1339/4885
US-20230030115-A1 RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF ROCK1, ROCK2, RHOA GSR 3801/4885GNAI3 173/4885GNAO1 506/4885
US-20200339581-A1 AMINO INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS TLR7, TLR1, TLR9 GSR 1003/4885GNAI3 79/4885GNAO1 155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.